Review



cleaved parp  (Santa Cruz Biotechnology)


Bioz Verified Symbol Santa Cruz Biotechnology is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 96
      Buy from Supplier

    Structured Review

    Santa Cruz Biotechnology cleaved parp
    <t>DHODH</t> inhibition using orludodstat impairs cell proliferation in various AR-negative PCa cells. Brightfield visualisation of PC3 cells (A), DU145 cells (C) and LASCPC-01 (E), with and without 96 h orludodstat treatment at 100 nM. Scale bar 100 μm. PC3 (B), DU145 (D) and LASCPC-01 (F) cell number, following 96 h orludodstat treatment at 100 nM. PC3 (G), DU145 (H) and LASCPC-01 (I) cell viability after 96 h of different concentrations of orludodstat treatment. Results from one representative out of three independent experiments are shown (average and S.E.M.). J) Western Blot assessment of <t>PARP</t> cleavage, a marker of apoptosis, following 24 h orludodstat treatment. PC3 cell analysis following 96 h orludodstat treatment using flow cytometry (K), showing a blockade in S phase (L). DU145 cell analysis following 96 h orludodstat treatment using flow cytometry (M), showing a blockade in S phase (N). Rescue experiments of 96 h orludodstat treatment with 750 μM uridine in PC3 (O), DU145 (P), and LASCPC-01 (Q) cells. Results from three independent experiments are shown (average and S.E.M.). For panels A, C, E, and J, representative images of one independent experiment, out of three independent experiments, are shown. ∗ p < 0.05, ∗∗ p < 0.01 ∗∗∗ p < 0.001.
    Cleaved Parp, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 96/100, based on 2143 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cleaved parp/product/Santa Cruz Biotechnology
    Average 96 stars, based on 2143 article reviews
    cleaved parp - by Bioz Stars, 2026-06
    96/100 stars

    Images

    1) Product Images from "Targeting DHODH reveals a metabolic vulnerability in AR-positive and AR-negative prostate cancer cells via pyrimidine synthesis and metabolic crosstalk with the TCA and urea cycles"

    Article Title: Targeting DHODH reveals a metabolic vulnerability in AR-positive and AR-negative prostate cancer cells via pyrimidine synthesis and metabolic crosstalk with the TCA and urea cycles

    Journal: Molecular Metabolism

    doi: 10.1016/j.molmet.2025.102316

    DHODH inhibition using orludodstat impairs cell proliferation in various AR-negative PCa cells. Brightfield visualisation of PC3 cells (A), DU145 cells (C) and LASCPC-01 (E), with and without 96 h orludodstat treatment at 100 nM. Scale bar 100 μm. PC3 (B), DU145 (D) and LASCPC-01 (F) cell number, following 96 h orludodstat treatment at 100 nM. PC3 (G), DU145 (H) and LASCPC-01 (I) cell viability after 96 h of different concentrations of orludodstat treatment. Results from one representative out of three independent experiments are shown (average and S.E.M.). J) Western Blot assessment of PARP cleavage, a marker of apoptosis, following 24 h orludodstat treatment. PC3 cell analysis following 96 h orludodstat treatment using flow cytometry (K), showing a blockade in S phase (L). DU145 cell analysis following 96 h orludodstat treatment using flow cytometry (M), showing a blockade in S phase (N). Rescue experiments of 96 h orludodstat treatment with 750 μM uridine in PC3 (O), DU145 (P), and LASCPC-01 (Q) cells. Results from three independent experiments are shown (average and S.E.M.). For panels A, C, E, and J, representative images of one independent experiment, out of three independent experiments, are shown. ∗ p < 0.05, ∗∗ p < 0.01 ∗∗∗ p < 0.001.
    Figure Legend Snippet: DHODH inhibition using orludodstat impairs cell proliferation in various AR-negative PCa cells. Brightfield visualisation of PC3 cells (A), DU145 cells (C) and LASCPC-01 (E), with and without 96 h orludodstat treatment at 100 nM. Scale bar 100 μm. PC3 (B), DU145 (D) and LASCPC-01 (F) cell number, following 96 h orludodstat treatment at 100 nM. PC3 (G), DU145 (H) and LASCPC-01 (I) cell viability after 96 h of different concentrations of orludodstat treatment. Results from one representative out of three independent experiments are shown (average and S.E.M.). J) Western Blot assessment of PARP cleavage, a marker of apoptosis, following 24 h orludodstat treatment. PC3 cell analysis following 96 h orludodstat treatment using flow cytometry (K), showing a blockade in S phase (L). DU145 cell analysis following 96 h orludodstat treatment using flow cytometry (M), showing a blockade in S phase (N). Rescue experiments of 96 h orludodstat treatment with 750 μM uridine in PC3 (O), DU145 (P), and LASCPC-01 (Q) cells. Results from three independent experiments are shown (average and S.E.M.). For panels A, C, E, and J, representative images of one independent experiment, out of three independent experiments, are shown. ∗ p < 0.05, ∗∗ p < 0.01 ∗∗∗ p < 0.001.

    Techniques Used: Inhibition, Western Blot, Marker, Cell Analysis, Flow Cytometry



    Similar Products

    cleaved parp 1  (Cell Signaling Technology Inc)
    98
    Cell Signaling Technology Inc cleaved parp 1
    Cleaved Parp 1, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cleaved parp 1/product/Cell Signaling Technology Inc
    Average 98 stars, based on 1 article reviews
    cleaved parp 1 - by Bioz Stars, 2026-06
    98/100 stars
    		  Buy from Supplier
    anti cleaved parp  (Proteintech)
    96
    Proteintech anti cleaved parp
    Anti Cleaved Parp, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti cleaved parp/product/Proteintech
    Average 96 stars, based on 1 article reviews
    anti cleaved parp - by Bioz Stars, 2026-06
    96/100 stars
    		  Buy from Supplier
    cleaved parp 1 d214 abways technology cy5035  (Proteintech)
    95
    Proteintech cleaved parp 1 d214 abways technology cy5035
    Cleaved Parp 1 D214 Abways Technology Cy5035, supplied by Proteintech, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cleaved parp 1 d214 abways technology cy5035/product/Proteintech
    Average 95 stars, based on 1 article reviews
    cleaved parp 1 d214 abways technology cy5035 - by Bioz Stars, 2026-06
    95/100 stars
    		  Buy from Supplier
    cleaved parp  (Santa Cruz Biotechnology)
    96
    Santa Cruz Biotechnology cleaved parp
    <t>DHODH</t> inhibition using orludodstat impairs cell proliferation in various AR-negative PCa cells. Brightfield visualisation of PC3 cells (A), DU145 cells (C) and LASCPC-01 (E), with and without 96 h orludodstat treatment at 100 nM. Scale bar 100 μm. PC3 (B), DU145 (D) and LASCPC-01 (F) cell number, following 96 h orludodstat treatment at 100 nM. PC3 (G), DU145 (H) and LASCPC-01 (I) cell viability after 96 h of different concentrations of orludodstat treatment. Results from one representative out of three independent experiments are shown (average and S.E.M.). J) Western Blot assessment of <t>PARP</t> cleavage, a marker of apoptosis, following 24 h orludodstat treatment. PC3 cell analysis following 96 h orludodstat treatment using flow cytometry (K), showing a blockade in S phase (L). DU145 cell analysis following 96 h orludodstat treatment using flow cytometry (M), showing a blockade in S phase (N). Rescue experiments of 96 h orludodstat treatment with 750 μM uridine in PC3 (O), DU145 (P), and LASCPC-01 (Q) cells. Results from three independent experiments are shown (average and S.E.M.). For panels A, C, E, and J, representative images of one independent experiment, out of three independent experiments, are shown. ∗ p < 0.05, ∗∗ p < 0.01 ∗∗∗ p < 0.001.
    Cleaved Parp, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cleaved parp/product/Santa Cruz Biotechnology
    Average 96 stars, based on 1 article reviews
    cleaved parp - by Bioz Stars, 2026-06
    96/100 stars
    		  Buy from Supplier
    parp 1  (Santa Cruz Biotechnology)
    96
    Santa Cruz Biotechnology parp 1
    <t>DHODH</t> inhibition using orludodstat impairs cell proliferation in various AR-negative PCa cells. Brightfield visualisation of PC3 cells (A), DU145 cells (C) and LASCPC-01 (E), with and without 96 h orludodstat treatment at 100 nM. Scale bar 100 μm. PC3 (B), DU145 (D) and LASCPC-01 (F) cell number, following 96 h orludodstat treatment at 100 nM. PC3 (G), DU145 (H) and LASCPC-01 (I) cell viability after 96 h of different concentrations of orludodstat treatment. Results from one representative out of three independent experiments are shown (average and S.E.M.). J) Western Blot assessment of <t>PARP</t> cleavage, a marker of apoptosis, following 24 h orludodstat treatment. PC3 cell analysis following 96 h orludodstat treatment using flow cytometry (K), showing a blockade in S phase (L). DU145 cell analysis following 96 h orludodstat treatment using flow cytometry (M), showing a blockade in S phase (N). Rescue experiments of 96 h orludodstat treatment with 750 μM uridine in PC3 (O), DU145 (P), and LASCPC-01 (Q) cells. Results from three independent experiments are shown (average and S.E.M.). For panels A, C, E, and J, representative images of one independent experiment, out of three independent experiments, are shown. ∗ p < 0.05, ∗∗ p < 0.01 ∗∗∗ p < 0.001.
    Parp 1, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/parp 1/product/Santa Cruz Biotechnology
    Average 96 stars, based on 1 article reviews
    parp 1 - by Bioz Stars, 2026-06
    96/100 stars
    		  Buy from Supplier

    Image Search Results


    DHODH inhibition using orludodstat impairs cell proliferation in various AR-negative PCa cells. Brightfield visualisation of PC3 cells (A), DU145 cells (C) and LASCPC-01 (E), with and without 96 h orludodstat treatment at 100 nM. Scale bar 100 μm. PC3 (B), DU145 (D) and LASCPC-01 (F) cell number, following 96 h orludodstat treatment at 100 nM. PC3 (G), DU145 (H) and LASCPC-01 (I) cell viability after 96 h of different concentrations of orludodstat treatment. Results from one representative out of three independent experiments are shown (average and S.E.M.). J) Western Blot assessment of PARP cleavage, a marker of apoptosis, following 24 h orludodstat treatment. PC3 cell analysis following 96 h orludodstat treatment using flow cytometry (K), showing a blockade in S phase (L). DU145 cell analysis following 96 h orludodstat treatment using flow cytometry (M), showing a blockade in S phase (N). Rescue experiments of 96 h orludodstat treatment with 750 μM uridine in PC3 (O), DU145 (P), and LASCPC-01 (Q) cells. Results from three independent experiments are shown (average and S.E.M.). For panels A, C, E, and J, representative images of one independent experiment, out of three independent experiments, are shown. ∗ p < 0.05, ∗∗ p < 0.01 ∗∗∗ p < 0.001.

    Journal: Molecular Metabolism

    Article Title: Targeting DHODH reveals a metabolic vulnerability in AR-positive and AR-negative prostate cancer cells via pyrimidine synthesis and metabolic crosstalk with the TCA and urea cycles

    doi: 10.1016/j.molmet.2025.102316

    Figure Lengend Snippet: DHODH inhibition using orludodstat impairs cell proliferation in various AR-negative PCa cells. Brightfield visualisation of PC3 cells (A), DU145 cells (C) and LASCPC-01 (E), with and without 96 h orludodstat treatment at 100 nM. Scale bar 100 μm. PC3 (B), DU145 (D) and LASCPC-01 (F) cell number, following 96 h orludodstat treatment at 100 nM. PC3 (G), DU145 (H) and LASCPC-01 (I) cell viability after 96 h of different concentrations of orludodstat treatment. Results from one representative out of three independent experiments are shown (average and S.E.M.). J) Western Blot assessment of PARP cleavage, a marker of apoptosis, following 24 h orludodstat treatment. PC3 cell analysis following 96 h orludodstat treatment using flow cytometry (K), showing a blockade in S phase (L). DU145 cell analysis following 96 h orludodstat treatment using flow cytometry (M), showing a blockade in S phase (N). Rescue experiments of 96 h orludodstat treatment with 750 μM uridine in PC3 (O), DU145 (P), and LASCPC-01 (Q) cells. Results from three independent experiments are shown (average and S.E.M.). For panels A, C, E, and J, representative images of one independent experiment, out of three independent experiments, are shown. ∗ p < 0.05, ∗∗ p < 0.01 ∗∗∗ p < 0.001.

    Article Snippet: Lysis buffer K was made with 20 mM Na 2 HPO 4 , 0.15 M NaCl, 0.1% NP40, 5 mM EDTA, and CHAPS 0.01 % proteinase inhibitor (Sigma–Aldrich #P8340-5 ML) and a phosphatase inhibitor cocktail tablet (Roche#04-906-837-001) was added for 10 mL of Lysis buffer K. For the apoptosis signaling, western blot analysis was performed with primary antibodies DHODH (Cell Signaling Technology #26381), cleaved PARP (Santa Cruz Biotechnology #sc-56196), α-tubulin (Cell Signaling Technology #2125); ribosomal protein S6 (Santa Cruz Biotechnology #sc-74459); and AR statut (Santa Cruz Biotechnology #sc-7305).

    Techniques: Inhibition, Western Blot, Marker, Cell Analysis, Flow Cytometry